

Bundled Payments for Care Improvement (BPCI) Advanced Annual Check-in Questionnaire

[illegible]

1

7

Purpose:

Participants' activities and barriers related to designing and implementing the BPCI Advanced Model

Instructions:

The first part of the study was a pilot study. The purpose of the pilot study was to determine the feasibility of the study and to estimate the sample size required for the main study. The pilot study was conducted with 10 participants. The results of the pilot study showed that the study was feasible and that the sample size required for the main study was 100 participants.

The main study was conducted with 100 participants. The participants were recruited from a local community center. The participants were randomly assigned to two groups: the experimental group and the control group. The experimental group received the intervention, and the control group did not receive the intervention. The intervention was a 12-week program of physical activity and nutrition education. The participants in the experimental group were instructed to engage in 150 minutes of moderate-intensity physical activity per week and to consume a diet that was rich in fruits, vegetables, and whole grains. The participants in the control group were instructed to continue with their current level of physical activity and diet.



The primary outcome of the study was the change in body mass index (BMI) from baseline to 12 weeks. The secondary outcomes were the change in waist circumference, blood pressure, and blood glucose levels. The results of the study showed that the participants in the experimental group had a significantly greater reduction in BMI, waist circumference, blood pressure, and blood glucose levels compared to the participants in the control group.

The results of the study suggest that a 12-week program of physical activity and nutrition education can effectively reduce BMI, waist circumference, blood pressure, and blood glucose levels in a community-based population. These findings have important implications for the development of public health interventions aimed at reducing the burden of chronic diseases.


Diagram illustrating the location of the *rrd* gene on the *E. coli* genome. The genome is shown as a circular map with various genes labeled. The *rrd* gene is located on the right side of the map, between the *rrd* and *rrd* genes.

-

D r d d r
d r R d r D r r d
D r d r d d d D R d r
D

- 
- 

“Open with”

- 



no later than **September 23, 2019 at 11:59PM ET** [Click here to download](#)
 the [document](#) and [submit your comments](#) to the [rulemaking docket](#) on [Regulations.gov](#).
 Comments received by the Department on or before the deadline will be considered in the
 development of the final rule. Comments received after the deadline may be considered if they
 are submitted in a timely manner and the Department determines that the comments are
 relevant to the rulemaking process. Comments received after the deadline may be considered if they
 are submitted in a timely manner and the Department determines that the comments are
 relevant to the rulemaking process. [Click here to download](#)

M r d M r r d d d r
r rd r M
d d M

101

☐
☐
☐
☐
☐

☐
☐
☐
☐

1

□ □ □ □

□ □ □ □ □

□ □ □ □ □

100

Participant Profile

9

1001

Care Redesign Plan

1111

□ r □ □ □ □ □ D □ □ □ □ r □ □ □

☐

☐

☐

[illegible]

D **r** **d** **d** **R**

☐
☐
☐
☐
☐

$\frac{1}{n} \sum_{i=1}^n \left(\frac{1}{m_i} \sum_{j=1}^{m_i} x_{ij} \right) = \frac{1}{n} \sum_{i=1}^n \bar{x}_i$

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

CEHRT Use

1. *To meet this criterion, at least 75 percent of eligible clinicians in each participating APM Entity group, or each hospital if hospitals are the APM Entities, to use CEHRT to document and communicate clinical care.*



[illegible]

☐
☐
☐

1. $\frac{1}{2} \frac{d}{dt} \left(\frac{1}{2} m v^2 \right) = \frac{1}{2} m v \frac{dv}{dt}$
 $\frac{1}{2} m v \frac{dv}{dt} = \frac{1}{2} m v \frac{dv}{dt}$

□ □ □ □ □ □ □ □ □ □ □ □ □

Partner Agreements

1. **Definition:** A **Discrete Event Simulation (DES)** is a type of simulation that models the operation of a system as a sequence of events occurring at discrete points in time.

□ □ □ □ □

r d r r

□ □ □ □ □

The diagram shows a 3D ribbon representation of a protein structure. Residues are highlighted in yellow and red. The yellow residues are: 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836,

□ □ □ □ □

[illegible]

- | | | | | |
|--|--------------------------|--------------------------|--------------------------|--------------------------|
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

4.

[illegible]

Diagram illustrating the structure of a DNA sequence. The sequence is represented by a horizontal bar divided into segments. The segments are labeled with letters: D, r, d, r. The segments are color-coded: D is blue, r is green, d is red, and r is green. The segments are arranged in a sequence: D, r, d, r. The segments are connected by lines, indicating a continuous sequence.

- □ □ □

□ □ □ □ □ □ □ □ □ □ □ □ □

115

[illegible]

☐
☐
☐
☐
☐

Compliance Plan

- ## Waivers (Fraud & Abuse Waivers and Medicare Payment Policy Waivers)

Participant Profile Selection Does Not Limit Use of Waivers”

[illegible]

□ □ □

[illegible]

☐

☐

☐

[illegible]

-  

111

[illegible]

333

☐ If you selected 'Yes' to ques ☐ ☐d ☐r

☐

☐

☐

☐

☐

[illegible]

☐
☐
☐
☐
☐
☐

[illegible]

- 



□ □ □

[illegible]

□ □ □

[illegible]

word

d r

□r□□□□□□r□□ □□□□r□□□□□□ □□□□□□□□ □□□□ □□□r□□□d□□□□□□

11 of 11

□ □ □

☐ If selected 'Other' to question

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □

□ □ □ □ □

5

☐

☐

☐

□ □ □ □

[illegible]

1001

1001



5

[illegible]

BPCI Advanced Impact



9



☐ If selected 'Yes' to either question 1 or 2, ☐ and ☐

9

9

☐☐

1

9

7

☐☐
☐☐
☐☐

[illegible]

5

5




1

d

□ □ □ □ □ □ □ □ □

□ □ □ □ □ □ □ **R** □ □ □ □ □ □ □

☐ ☒ ☐ or ☐

r d

Document Submission

□

$\frac{d}{dt} \left(\frac{1}{r^2} \right) = -\frac{2}{r^3} \frac{dr}{dt}$

□

1

[illegible]

- ☐
☐
☐
☐
☐

Self-disclosed Investigations or Sanctions

[illegible]

- □ □

- [illegible]

- □ □ □ □ □ □

Other Issues Not Previously Listed

-